Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2014—To meet the needs of today’s next-generation sequencing projects, Aurora Biomed offers the VERSA NGS Library Prep Workstation for high throughput preparation of sample libraries. VERSA enables automated processing of up to 96 libraries in parallel with the high precision needed for quality results.
February—Caris Life Sciences presented a study at the December 2013 CTCR-AACR San Antonio Breast Cancer Symposium on identifying potentially actionable therapeutic targets and clinical strategies for triple-negative breast cancer (TNBC). The biomarker data used for the study were obtained using the company’s tumor profiling service, Caris Molecular Intelligence.
February 2014—Leica Biosystems announced a partnership with EyesFinder, a developer of visual search technology, to create decision support tools for pathologists.
February 2014—Myriad Genetics presented clinical data from a research study showing that its HRD (homologous recombination deficiency) test predicted platinum response in patients with triple-negative breast cancer (P=0.0003). The HRD score predicted, with a sensitivity of 100 percent, all of the patients who experienced a complete response after presurgical treatment with platinum. In addition, the results showed that the HRD score was generalizable across all breast cancer subtypes.
February 2014—Nanosphere received FDA clearance for its Verigene Gram-Negative Blood Culture (BC-GN) Test, an in vitro diagnostic test that determines resistance to commonly used antibiotics up to two to three days faster than conventional identification methods. Among the critical genetic markers of antibiotic resistance identified by Verigene BC-GN are five genes that can identify carbapenem-resistant Enterobacteriaceae.
February 2014—Life Technologies released general-purpose reagents (GPRs) for the development of molecular diagnostic assays based on qPCR and capillary electrophoresis (CE). GPR products are for laboratory use and come with a higher quality assurance than research-use-only products. For CE (for sequencing and fragment analysis), BigDye Terminator Cycle Sequencing Reagents provide the required components for cycle sequencing reactions in a premixed format. They are optimized for longer, higher-quality reads with uniform peak heights and optimal signal balance and are appropriate for a range of applications, including de novo sequencing and resequencing.
February—NanoString Technologies announced the availability of the Prosigna Breast Cancer Prognostic Gene Signature Assay beginning in the first quarter of this year.
January 2014—Air Science introduced its new Purair Eco line of energy-saving ductless fume hoods designed for chemical and particulate protection over a broad range of laboratory and industrial applications.
January 2014—Mettler Toledo has embedded radio- frequency identification tags in all of its premium Rainin air displacement pipettes, including its recently released E4 XLS electronic model. RFID tagging helps labs establish advanced calibration schedules through heightened pipette tracking.
January 2014—Spring Bioscience has added the Anti-PTEN (SP218) rabbit monoclonal immunohistochemistry antibody to its portfolio of antibodies for cancer research.
